PYCR3

Across TCGA pan-cancer cohorts, PYCR3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PYCR3 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PYCR3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PYCR3 expression acts as an unfavorable survival marker.

LSCC, GBM, and PDAC are the cancer types where PYCR3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.336	1.000	.013	10	view →
GBM	OS	Median	All	0.391	0.661	<.001	9	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	9	view →
HNSC	OS	Tertile	All	0.930	1.000	.022	8	view →
CCRCC	OS	Tertile	All	0.786	0.950	.022	6	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PYCR3–LSCC (DFS)

Open the LSCC breakdown →